QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 relmada-therapeutics-cmo-raj-s-pruthi-purchases-55000-shares-in-open-market-on-august-29-2025

On August 29, 2025, Raj S. Pruthi, MD, Chief Medical Officer-Urology of Relmada Therapeutics, Inc. (the "Company"), pur...

 relmada-therapeutics-q2-eps-030-misses-002-estimate

Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate o...

 relmada-therapeutics-terminates-license-agreement-with-dr-charles-e-inturrisi--dr-paolo-manfredi-ends-esmethadone-development-program

-SEC Filing

 relmada-therapeutics-q1-gaap-eps-058-misses-052-estimate

Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate o...

 relmada-therapeutics-initial-data-from-phase-2-study-of-ndv-01-shows-strong-clinical-activity-in-bcg-nave-and-bcg-unresponsive-patients

90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept fo...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION